缺血性心脏病合并心力衰竭的临床治疗体会

目的观察比较曲美他嗪和左卡尼汀治疗缺血性心脏病合并心力衰竭的临床效果。方法选取我院自2006年1月～2009年12月之间收治的缺血性心脏病合并心力衰竭的患者126例,随机分为A组(曲美他嗪组)和B组(左卡尼汀组),每组各63例,治疗周期均为8周,比较两组治疗效果。结果 A组(曲美他嗪组)显效7例,有效35例,总有效率为66.7%;B组(左卡尼汀组)显效8例,有效45例,总有效率为84.1%。两组比较差异显著(P<0.01)。A组(曲美他嗪组)总计发生不良反应4例,不良反应发生率为6.4%;B组(左卡尼汀组)总计发生不良反应11例,不良反应发生率为17.5%。两组比较差异显著(P<0.01)。结论左卡尼汀治疗缺血性心脏病合并心力衰竭效果较好但并发症较多,临床应根据患者具体情况选择用药。

Objective To compare the trimetazidine and L-carnitine treatment of ischemic heart disease with heart failure and clinical effects. Methods in our hospital from January 2006～December 2009 were admitted between the heart failure of ischemic heart disease with 126 patients were randomly divided into group A （trimetazidine group） and B （L-carnitine group） of the 63 cases, the treatment cycle was 8 weeks, compared treatment effects. Results A group （of trimetazidine group） in 7 cases markedly effective in 35 cases, total effective rate was 66.7%; B group （L-carnitine group） 8 cases were markedly effective in 45 cases, total effective rate was 84.1%. Significant difference between the two groups （P〈0.01）. A （trimetazidine group） a total of 4 cases of adverse reaction, adverse reaction rate was 6.4%; B group （L-carnitine group） a total of 11 cases of adverse reaction, adverse reaction rate was 17.5%. Signifi cant difference between the two groups （P〈0.01）. Conclusion L-carnitine treatment of ischemic heart failure effect of the merger better but more complications, the clinical circumstances in accordance with patient choice of drugs.